Company |
Product |
Description |
Indication |
Status |
Date |
Phase II | |||||
Actinogen Medical Ltd., of Sydney |
Xanamem |
Blocks activity of 11beta-HSD1 |
Mild Alzheimer's disease |
Enrolled the final patient in the XanADu trial; 186-patient trial is comparing Xanamem to placebo in patients with mild dementia due to AD; results expected in the second quarter of 2019 |
11/26/18 |
Opthea Ltd., of Melbourne, Australia |
OPT-302 |
Soluble form of VEGFR-3 |
Wet age-related macular degeneration |
Last patient enrolled in the phase IIb trial, with total of 366; top-line data expected in the fourth quarter of 2019 |
11/26/18 |
Phase III | |||||
Foresee Pharmaceuticals Co. Ltd., of Taipei, Taiwan |
FP-001 (LMIS 25 mg) |
Leuprolide mesylate injectable suspension |
Advanced prostate cancer |
All patients completed participation in the single-arm study; 144 patients enrolled to receive 2 consecutive injections for aggregated treatment duration of 6 months; top-line data expected in the first quarter of 2019 |
11/26/18 |
|
Notes The date indicated refers to the BioWorld Clinical data table in which the news item can be found. For more information about individual companies and/or products, see Cortellis. | |||||